[{"id":"c9fa59c0-ee9b-4c5f-baf7-8f04f47fe653","acronym":"","url":"https://clinicaltrials.gov/study/NCT05630794","created_at":"2022-11-30T18:57:52.049Z","updated_at":"2025-02-25T13:41:21.187Z","phase":"Phase 1","brief_title":"Testing ONC201 to Prevent Colorectal Cancer","source_id_and_acronym":"NCT05630794","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL","pipe":"","alterations":" ","tags":["BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/30/2025","start_date":" 03/30/2025","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-02-21"},{"id":"12f81b1d-451f-4a1e-b774-333646268edd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05009992","created_at":"2024-06-15T04:08:56.168Z","updated_at":"2024-07-02T16:34:26.237Z","phase":"Phase 2","brief_title":"Combination Therapy for the Treatment of Diffuse Midline Gliomas","source_id_and_acronym":"NCT05009992","lead_sponsor":"University of California, San Francisco","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone) • paxalisib (GDC-0084)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 10/20/2021","start_date":" 10/20/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2024-06-13"},{"id":"c7e83498-ae4f-45ae-8bbe-548a13445d7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05013437","created_at":"2021-08-27T13:53:01.565Z","updated_at":"2024-07-02T16:35:11.879Z","phase":"Phase 1","brief_title":"Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma","source_id_and_acronym":"NCT05013437","lead_sponsor":"Koen van Besien","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e captisol-enabled melphalan"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-04-02"},{"id":"d7d5dd0d-e489-4e4c-a9c5-5f9b23ef89a2","acronym":"BIOMEDE 2","url":"https://clinicaltrials.gov/study/NCT05476939","created_at":"2022-07-27T13:54:43.500Z","updated_at":"2024-07-02T16:35:16.753Z","phase":"Phase 3","brief_title":"Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0","source_id_and_acronym":"NCT05476939 - BIOMEDE 2","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Modeyso (dordaviprone)"],"overall_status":"Recruiting","enrollment":" Enrollment 409","initiation":"Initiation: 09/29/2022","start_date":" 09/29/2022","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2031","study_completion_date":" 09/01/2031","last_update_posted":"2024-03-01"},{"id":"d6659ed0-a160-442d-9ebc-6110d6f497a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03161652","created_at":"2022-07-22T08:56:46.266Z","updated_at":"2024-07-02T16:35:39.044Z","phase":"Phase 2","brief_title":"Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema","source_id_and_acronym":"NCT03161652","lead_sponsor":"Carmen Clapp","biomarkers":" PRL","pipe":"","alterations":" ","tags":["PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lucentis (ranibizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/24/2017","start_date":" 05/24/2017","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-08-25"},{"id":"985c92d2-fc43-4e40-b180-09c113e1c56e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03394027","created_at":"2021-01-18T16:44:56.063Z","updated_at":"2024-07-02T16:36:05.006Z","phase":"Phase 2","brief_title":"ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma","source_id_and_acronym":"NCT03394027","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • EGFR positive • PGR negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • EGFR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/17/2018","start_date":" 01/17/2018","primary_txt":" Primary completion: 03/18/2021","primary_completion_date":" 03/18/2021","study_txt":" Completion: 10/07/2021","study_completion_date":" 10/07/2021","last_update_posted":"2022-08-23"},{"id":"00fc36b5-fb5c-4743-870c-ddf1ebb39ac5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04854044","created_at":"2021-04-22T21:53:11.171Z","updated_at":"2024-07-02T16:36:30.399Z","phase":"Phase 1b","brief_title":"ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma","source_id_and_acronym":"NCT04854044","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" SOX2 • NANOG","pipe":"","alterations":" ","tags":["SOX2 • NANOG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2021","start_date":" 05/01/2021","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2021-05-12"},{"id":"7f03c3f7-74dd-4581-a823-0407a28b50a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03457389","created_at":"2021-01-18T17:02:43.890Z","updated_at":"2024-07-02T16:36:48.260Z","phase":"","brief_title":"Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma","source_id_and_acronym":"NCT03457389","lead_sponsor":"Seoul National University Hospital","biomarkers":" PRL","pipe":"","alterations":" ","tags":["PRL"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/22/2018","start_date":" 02/22/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2020-03-18"},{"id":"c358d7e4-427f-4382-9fc0-367764b779e6","acronym":"RACTAC","url":"https://clinicaltrials.gov/study/NCT04224441","created_at":"2021-01-27T20:01:13.963Z","updated_at":"2024-07-02T16:36:51.430Z","phase":"Phase 2","brief_title":"Repurposing Chlorpromazine in the Treatment of Glioblastoma","source_id_and_acronym":"NCT04224441 - RACTAC","lead_sponsor":"Marco G Paggi, MD, PhD","biomarkers":" IDH2 • MGMT","pipe":"","alterations":" ","tags":["IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • chlorpromazine"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 12/15/2019","start_date":" 12/15/2019","primary_txt":" Primary completion: 06/15/2022","primary_completion_date":" 06/15/2022","study_txt":" Completion: 12/15/2022","study_completion_date":" 12/15/2022","last_update_posted":"2020-01-13"}]